Vanguard Capital Management
PCVX icon

Vanguard Capital Management’s Vaxcyte PCVX Stock Holding History

Vanguard Capital Management’s Portfolio PCVX Stock Details PCVX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$369M Buy
6,348,679
+81,978
+1% +$4.45M 0.01% 820
2026
Q1 		$364M Buy
+6,266,701
New +$340M 0.01% 771

Other funds holding PCVX

JT
Jupiter Topco New York $245B AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return

Vanguard Capital Management's PCVX Position: Q2 2026 in Review

Vanguard Capital Management increased its Vaxcyte (PCVX) stake by 1.3% in Q2 2026, buying an estimated $4.45M and bringing the position to 6,348,679 shares worth $369M. The position accounts for 0.01% of the portfolio, ranked #820.

Vanguard Capital Management first reported a position in PCVX in Q1 2026 and has held it in 2 quarters since. 307 funds tracked by Wall St. Rank hold PCVX as of Q2 2026.

  • Vanguard Capital Management held 6,348,679 shares of Vaxcyte worth $369M as of Q2 2026.
  • Vanguard Capital Management bought 81,978 Vaxcyte shares in Q2 2026, an estimated $4.45M.
  • Vaxcyte made up 0.01% of Vanguard Capital Management's portfolio in Q2 2026, its #820 holding.
  • Vanguard Capital Management first reported a position in Vaxcyte in Q1 2026 and has held it in 2 quarters since.
  • 307 funds tracked by Wall St. Rank held Vaxcyte as of Q2 2026.

Based on Vanguard Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.